Avion Pharmaceuticals Announces the FDA Approval and Availability of DHIVY™
(February 15, 2022) – Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be easily divided and individualized. Avion gained approval for DHIVY from the FDA in November 2021. This uniquely designed tablet has four segments, which enables more precise medication dosing, directly addressing a market need. Click here to learn more about Avion Pharmaceuticals and DHIVY™.